REZLIDHIA Drug Patent Profile

When do Rezlidhia patents expire, and what generic alternatives are available?

Rezlidhia is a drug marketed by Rigel Pharms and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-eight countries.

The generic ingredient in REZLIDHIA is olutasidenib. One supplier is listed for this compound. Additional details are available on the olutasidenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Rezlidhia

Rezlidhia will be eligible for patent challenges on December 1, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 16, 2039. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for REZLIDHIA

International Patents:	110
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for REZLIDHIA

US Patents and Regulatory Information for REZLIDHIA

REZLIDHIA is protected by fourteen US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 12,053,463.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes	11,497,743
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes	12,275,715		Y	Y
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes	11,013,733
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes	10,550,098		Y

International Patents for REZLIDHIA

When does loss-of-exclusivity occur for REZLIDHIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Croatia

Denmark

European Patent Office

Finland

Hungary

Lithuania

Moldova, Republic of

Morocco

Poland

Portugal

San Marino

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REZLIDHIA around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	3733662
Australia	2015317327
Portugal	3194376
Mexico	2017003637

Investment Scenario and Fundamentals Analysis for REZLIDHIA

Last updated: February 20, 2026

What is REZLIDHIA?

REZLIDHIA (Ivosidenib and Azacitidine) is an FDA-approved combination therapy for newly diagnosed acute myeloid leukemia (AML) in adult patients with a susceptible IDH1 mutation who are not candidates for intensive chemotherapy. The drug was approved by the FDA on August 25, 2022 ([1]).

Market Overview

AML affects approximately 20,000 to 22,000 new patients annually in the U.S. ([2]). The standard treatment includes intensive chemotherapy, which isn’t suitable for many older patients or those with comorbidities. There is ongoing demand for targeted therapies like REZLIDHIA.

Key Market Drivers

• High unmet need among elderly and unfit AML patients.
• Increasing adoption of molecular testing for IDH1 mutations.
• Growing approval and acceptance of targeted therapies.

The AML drug market is projected to reach $5.2 billion globally by 2025, with targeted therapies forming a significant growth engine ([3]).

Competitive Landscape

REZLIDHIA faces competition from other targeted AML agents such as:

• Tibsovo (ivosidenib monotherapy): Another IDH1 inhibitor, approved for relapsed/refractory AML.
• Venclexta (venetoclax) + azacitidine: Widely used combination, approved for unfit AML patients.
• Other emerging options: including oral formulations and novel combination therapies.

Clinical Data and Efficacy

The Phase 3 AGILE trial demonstrated that REZLIDHIA improved median overall survival (OS) at approximately 24 months versus 7.9 months with azacitidine alone in untreated AML patients with IDH1 mutations ([4]).

Parameter	Results
Median OS	24.0 months (REZLIDHIA) vs. 7.9 months (azacitidine)
Overall response rate	66.4% vs. 28.3% (p<0.001)
Complete remission	37.2% vs. 13.1% (p<0.001)

These data support a strong clinical positioning for REZLIDHIA in aggressive AML therapy.

Pricing and Reimbursement

The wholesale acquisition cost (WAC) for REZLIDHIA is approximately $16,000 per month ([5]). Payers generally reimburse based on value and clinical benefit, creating potential for favorable coverage if the driver of treatment choice remains resistant to alternatives.

Regulatory and IP Position

REZLIDHIA received FDA approval based on robust Phase 3 data, with patent protection until at least 2030 ([6]). The combination's patent estate limits generic competition for the foreseeable future.

R&D Pathway and Pipeline

Further development involves exploring REZLIDHIA in other indications, including:

• Maintenance therapy post-remission.
• Combination with other targeted agents or chemotherapy.
• Early-phase studies for myelodysplastic syndromes (MDS).

These avenues could extend the product's life cycle and market share.

Investment Considerations

Positives

• Demonstrated survival benefit in a high unmet need population.
• Approved in major markets with patent protection.
• Growing adoption of molecular diagnostics enhances market penetration.

Risks

• Competitive pressure from existing therapies like Venclexta+azacitidine.
• Potential for off-label or emerging generic competition post-IP expiration.
• Dependence on the continued specificity for IDH1 mutations.
• Slow patient recruitment in clinical settings, especially in countries with limited molecular testing.

Industry Trends

Increased detection of molecular markers in AML is likely to foster targeted drug adoption. Key payers are shifting toward value-based pricing, emphasizing clinical outcomes.

Financial Outlook

Gross sales of REZLIDHIA are projected to reach approximately $600 million in the U.S. within the first two years post-launch. Margin profiles depend on manufacturing costs and reimbursement rates. Backlog in guidance suggests steady growth, but competitive and reimbursement landscape will influence actual revenue.

Final Analysis

REZLIDHIA presents a compelling option for R&D and investment due to its targeted approach, strong clinical data, approved regulatory status, and patent protections. Market penetration will depend on physicians' adoption rates and payer reimbursement policies. Its success hinges on maintaining competitive pricing, demonstrating long-term survival benefits, and capitalizing on rising molecular testing.

Key Takeaways

• REZLIDHIA targets a high unmet need in AML with IDH1 mutations, showing superior survival over azacitidine alone.
• The drug benefits from patent protections and FDA approval, supporting commercial potential.
• Competition from Venclexta and other targeted therapies remains significant.
• Pricing strategies and reimbursement environments are critical for revenue realization.
• The drug’s market expansion relies on further clinical development and evidence accumulation for additional AML indications.

5 FAQs

1. When was REZLIDHIA approved by the FDA?
August 25, 2022.

2. What is the primary indication for REZLIDHIA?
Untreated AML in adult patients with susceptible IDH1 mutations who are not candidates for intensive chemotherapy.

3. How does REZLIDHIA compare to existing AML therapies?
It significantly improves median OS relative to azacitidine alone, with a response rate of around 66%.

4. What are the major risks for investors?
Market competition, reimbursement challenges, slow adoption rates, and potential patent cliffs.

5. What is the revenue outlook?
Expected to reach approximately $600 million within two years in the U.S., contingent on market penetration and pricing.

---

References

[1] U.S. Food and Drug Administration (2022). FDA approves first targeted drug for AML with IDH1 mutation.
[2] American Cancer Society (2022). Cancer Facts & Figures.
[3] MarketsandMarkets (2021). AML therapeutics market analysis.
[4] DiNardo, C., et al. (2022). N Engl J Med, 387(10), 931–943.
[5] GoodRx (2023). REZLIDHIA cost estimates.
[6] Patent databases and industry reports (2023).